| Autor: |
Marchetti, Marcello, Pinzi, Valentina, Fumagalli, Maria Luisa, Martin, Elena De, Morlino, Sara, Iezzoni, Cecilia, Fariselli, Laura |
| Předmět: |
|
| Zdroj: |
Journal of Radiosurgery & SBRT; 2022 Supplement, Vol. 8, p100-101, 2p |
| Abstrakt: |
Introduction: Pituitary adenomas (PA) represent one of the most common intracranial pathologies, accounting for 10-20% of intracranial tumors. Although PA are histologically benign, the neurological and physiological consequences can be devastating, particularly if these tumors involve the anterior optic pathways. Surgery is the first line treatment in many cases. However, about 30% of patients require additional treatment after microsurgery for recurrent or residual tumors. Radiosurgery (RS) represents a viable option as adjuvant treatment following incomplete surgical resection, tumor recurrence, or failure of medical therapy. The RS literature data report tumor control rate higher than 90% at 10 years. However, the concern about the optic neuropathy may limit the single session radiosurgery (sRS) indications. The aim of this study is to retrospectively evaluate the efficacy and safety of multi-session radiosurgery (mSRS) for such cases. Materials and methods: Forty-two patients treated by means of mRS between 2011 and 2019 have been analyzed. All patients have at least a post RS radiological (MRI), endocrinological and ophthalmological follow-up. Results: The median age at the time of mSRS was 54 years. Twenty-six (62%) patients had evidence of partial or total hypopituitarism before mSRS. Visual defects were present in 66.7% of patients. The median followup was 29.5 months (range 6-110 months). The median tumour volume pre-mSRS was 7070 mm3 (range, 1339 - 74530 mm3 ). The mean prescription dose was 25 Gy in 5 fractions. After the treatment, 33 patients (78,6 %) have stable disease, 7 (16.6 %) showed partial response; one patient (2.4%) had a complete response; one patient (2.4) experienced a tumor progression. One patient (2.4 %) developed mild visual worsening. None of the analyzed patients developed new or worsened hypopituitarism. Conclusion: Our results suggest that mRS can be proposed as a safe and effective treatment modality for patients suffering from recurrent or residual pituitary adenomas. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
